Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent
Robert L. Hudkins(State Street (United States)), Bruce Ruggeri, Susan Jones‐Bolin, Kathryn Hunter, John P. Mallamo, Sheila Miknyoczki, Mark A. Ator, Mark S. Albom, Lisa D. Aimone, Allison L. Zulli, Hugh Zhao, Ted L. Underiner(NRG Oncology), Hong Chang, Nadine C. Becknell(NRG Oncology), Thelma S. Angeles, Edward R. Bacon
Cited by 42
Related Papers
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
|Proceedings of the National Academy of Sciences|2008|723
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120
Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors
|Expert Opinion on Drug Discovery|2016|113